History
Soft tissue sarcoma (STS) is a collective term for malignant tumors that begin in the “soft tissues” rather than in bone. In the past, names were often given according to the appearance under the microscope, so the same disease was sometimes called by different names, or different diseases were classified under similar names. This confusion was an obstacle to comparing treatment outcomes and accumulating research.
From the mid-20th century, as pathology advanced, a system was established that evaluates “which tissue it originated from” together with “how aggressive it is (grade),” and as the principle of widely excising the tumor surgically was combined with radiation therapy, strategies for treating it without amputating the limbs expanded. From the 1990s onward, imaging technologies such as magnetic resonance imaging (MRI) made surgical planning more precise, and the standardization of needle biopsy helped reduce diagnostic delays.
The key to recent developments is the recognition that “soft tissue sarcoma is not a single disease but a group of dozens of different subtypes.” Because growth rate, pattern of metastasis, and drug response differ greatly by subtype, confirming the pathology again and establishing a multidisciplinary treatment plan at an experienced center is increasingly emphasized.
Recently, treatment has been advancing toward “selecting according to the subtype and the patient's situation” not only standard chemotherapy drugs but also targeted therapy, immunotherapy, and new drug combinations.
Causes
For most soft tissue sarcomas, it is difficult to explain “why it developed” with a single factor. In many people, no clear cause or lifestyle factor is identified, and it often occurs by chance. Therefore, “sure ways to prevent it” in the usual sense are still limited.
Nevertheless, situations that can raise the risk are known. Typically, a new sarcoma may develop years to decades later in an area that previously received radiation therapy. Radiation is a very important tool for treating cancer, but rarely, the genes of normal tissue can be damaged during treatment and a second cancer can develop.
An association with exposure to certain chemicals has also been raised. For example, certain angiosarcomas have been reported in occupational groups with long-term exposure to substances such as certain wood preservatives or herbicide ingredients, and vinyl chloride, which is used in plastic manufacturing. However, because these associations are influenced by the level of exposure, the study design, and other factors, one cannot conclude that “exposure will always cause it.”
When immune function is greatly reduced, special forms of sarcoma originating from vascular endothelial cells, such as Kaposi sarcoma, can increase. These cases are related to human herpesvirus 8 (HHV-8) infection, so their causes and treatment are handled differently from typical soft tissue sarcoma.
Genetic Epidemiology
“Heredity” in soft tissue sarcoma is usually divided into two layers. The first is when a person has a specific gene abnormality from birth that raises the overall risk of cancer. For example, Li-Fraumeni syndrome (LFS) is associated with changes in the tumor suppressor gene TP53 and increases the risk of several types of cancer, and soft tissue sarcoma can be included in its spectrum. In addition, in neurofibromatosis type 1 (NF1), the risk of malignant tumors arising from the peripheral nerve sheath can rise.
However, these “hereditary syndromes” account for a very small proportion of all soft tissue sarcomas. In most patients, it occurs without a family history. The second layer is gene changes that appear only within the tumor cells after the tumor develops. These are not inherited from parents but are “acquired changes” that arise as cells grow.
In some subtypes, a specific gene fusion is so characteristic that it is almost like a “fingerprint” and helps with diagnosis, and in other cases, a specific signaling pathway is overactivated and becomes a candidate for targeted therapy. Rather than treatment being determined automatically by genetic test results alone, it is recommended that they be interpreted together with the pathology findings, stage, surgical feasibility, and the patient's condition.
General Epidemiology
Soft tissue sarcoma is among the rarer of all cancers. Combining statistics from several countries, it is estimated at a few cases per 100,000 people each year, and the expression “less than about 1% of adult cancers” is often used. Because it is rare, even when a mass is first discovered, it may be regarded as a “benign lump” and watched, which can lead to delayed diagnosis.
It can occur anywhere, but it is relatively common in the limbs (especially the thigh), and it also occurs in the trunk and deep in the abdomen (the retroperitoneum). Because tumors deep in the abdomen are difficult to feel from the outside, they are sometimes discovered only after growing to some extent, through nonspecific symptoms such as abdominal pain, bloating, and constipation.
Age varies greatly by subtype. Overall, it tends to be more common after age 50, but some subtypes, such as rhabdomyosarcoma, are relatively common in children.
Metastasis (spread to other organs) occurs most commonly to the lungs. Lymph node metastasis is uncommon overall, but it can occur relatively more often in some subtypes, so it is important to reflect “subtype-specific features” in staging.
Pathogenesis
Soft tissue sarcoma is a cancer that begins in tissues that serve as the body's “support structures,” such as muscle, fat, blood vessels, nerves, and fibrous tissue. When the cells of these tissues (usually cells of mesenchymal lineage) accumulate genetic damage for various reasons, lose normal growth control, and proliferate, a tumor forms. As the tumor grows, it pushes aside or invades surrounding tissue and can travel to other organs through blood vessels or lymphatic vessels.
The key point is that the pathogenesis differs by subtype. In some subtypes, a relatively simple core genetic change (e.g., a specific gene fusion) is the starting point of tumor formation, and as a result a specific protein works excessively and makes the cells keep growing. Other subtypes show “complex genetic instability” with multiple overlapping genetic changes, and such cases may tend to be of high histological grade and aggressive.
Recent reviews explain that the microenvironment around the tumor (immune cells, blood vessels, fibrous tissue, etc.) affects treatment response and prognosis. Taken as a whole, soft tissue sarcoma is not a disease in which immunotherapy always works well, so an approach of distinguishing “responsive subtypes” from “less responsive subtypes” and choosing based on clinical trial evidence is emphasized.
Symptoms
The most common beginning of soft tissue sarcoma is “a painless lump.” Especially in the limbs, a firm mass can be felt under the skin or within the muscle, but because there is little pain, it is easy to dismiss. Because soft tissue is elastic, there may be little discomfort even until the tumor has grown fairly large.
Symptoms appear when the tumor grows or begins to press on surrounding structures. For example, pressing on a nerve can cause numbness, reduced sensation, and muscle weakness, and around muscles or joints, movement can become uncomfortable or be accompanied by pain. Compressing a blood vessel can cause swelling, and if bleeding and necrosis occur inside the tumor, pain can suddenly become severe.
Soft tissue sarcoma arising deep inside the abdomen or in the retroperitoneum may begin with nonspecific symptoms such as abdominal pain and indigestion instead of a noticeable lump. Because these symptoms overlap with common digestive diseases, imaging tests may be needed if the symptoms persist for a long time or gradually worsen.
Signs
The important “warning signs” on physical examination are size, location, and growth rate. In general, a mass that is larger than 5 cm or grows increasingly quickly should prompt more serious consideration of soft tissue sarcoma. In addition, a mass felt not just under the skin but below the fascia, that is, in a deep layer, has a high priority for evaluation.
If, when touched, the mass feels attached to the surrounding tissue (does not move well), feels firm, or is accompanied by skin discoloration or ulceration or changes that bleed easily, the possibility of malignancy should be considered. If it is located close to nerves or blood vessels, signs such as sensory abnormalities, muscle weakness, weakened pulses, and swelling of the extremities may appear.
Signs related to metastasis may include respiratory symptoms such as cough and shortness of breath (possible lung metastasis), as well as bone pain, general fatigue, and weight loss. Soft tissue sarcoma cannot be confirmed by these signs alone; ultimately, imaging tests and a biopsy are needed.
Screening
Soft tissue sarcoma is not a common disease, its subtypes are very diverse, and no screening test has been established for the general population for which “regular testing has a clear benefit.” Therefore, national screening is not carried out as it is for stomach cancer or colorectal cancer.
The most important “early detection strategy” is knowing the warning signs and getting evaluated quickly. Even if there is no pain, if a lump keeps growing, is 5 cm or larger, is felt in a deep layer, or is a mass of unknown cause that persists for more than 4 weeks, it is safe to consider imaging tests and, if necessary, a biopsy.
High-risk groups (e.g., areas that previously received radiation therapy, people with certain hereditary syndromes) can strengthen monitoring for changes in symptoms in consultation with their medical team. Even in this case, the realistic approach is to perform imaging early and refer to a specialized center if a new mass or pain develops.
Diagnosis
When soft tissue sarcoma is suspected, the key to “confirmation” is a biopsy. The shape of the tumor can be estimated with imaging tests, but distinguishing benign from malignant and confirming the subtype require examining the tissue under the microscope. Usually, methods that obtain tissue with a large needle, such as core needle biopsy, are widely used. In some cases, an incisional biopsy may be needed, but it is important to plan the biopsy tract so that it can be removed together during the subsequent surgery.
Imaging tests are very important for “assessing the extent” and “surgical planning.” For the limbs or the superficial trunk, magnetic resonance imaging (MRI) best shows the size of the tumor, fascial involvement, and its relationship to nerves and blood vessels. Ultrasound (US) helps with the initial evaluation of superficial masses or with guiding biopsy. For the abdomen or retroperitoneum, computed tomography (CT) is useful for identifying the anatomical extent.
Staging is the process of checking for metastasis. Because soft tissue sarcoma commonly metastasizes to the lungs, chest CT is often included. Positron emission tomography (PET-CT) can be used as an adjunct if necessary, but it is not mandatory in every case and is chosen according to the subtype and purpose.
An important “practical point” in the diagnostic process is accurate classification of subtype and grade by an experienced pathology department. Because treatment can differ greatly even within the same sarcoma, having the pathology reviewed again at a specialized center can be helpful.
Treatment
Treatment of soft tissue sarcoma is broadly divided into local treatment (surgery and radiation) and systemic treatment (chemotherapy, targeted therapy, and immunotherapy), and the combination varies according to the patient's stage, subtype, the location and size of the tumor, and surgical feasibility. A commonly emphasized principle is “starting treatment with an accurate plan from the outset,” because the initial treatment has a great effect on future recurrence and preservation of function.
For localized lesions, the most important treatment is surgery. The goal is to remove the tumor with a safe margin (resection margin) to lower the risk of local recurrence. For the limbs, surgery that secures a sufficient resection margin while preserving function is standard, and reconstructive surgery may accompany it when necessary.
Radiation therapy can be given before surgery (to shrink the tumor and optimize the extent of resection) or after surgery (to eliminate microscopic cancer cells that may remain). Systemic treatment is chosen according to the situation. For recurrent or metastatic disease, doxorubicin-based chemotherapy has traditionally been widely used, and targeted therapy or immunotherapy known to be effective for specific subtypes is to be chosen “when there is evidence.”
Throughout treatment, consultation within a multidisciplinary team (surgery, medical oncology, radiation oncology, radiology, pathology) is directly linked to prognosis. In particular, when the tumor is large or deep, or in an anatomically complex location such as retroperitoneal sarcoma, treatment at a specialized center is strongly recommended.
Prognosis
Prognosis means “how likely a cure is and how great the risk of recurrence or metastasis is.” Because soft tissue sarcoma has diverse subtypes, its prognosis also spans a very wide range. In general, the most important factors affecting prognosis are considered to be the size of the tumor, its depth (above or below the fascia), its grade (low grade vs. high grade), the status of the resection margins (whether complete resection was achieved), and the presence of metastasis at diagnosis.
For localized lesions, the risk of recurrence is lower when complete resection is possible, the grade is low, and the size is small. Conversely, large, deep, high-grade sarcomas carry a high risk of local recurrence or distant metastasis even after surgery, so additional treatment including radiation therapy or systemic therapy is discussed.
When there is metastasis, the treatment goal may change. Metastatic disease is often difficult to cure, but the aim is to shrink the tumor with treatment to relieve symptoms and extend survival. In some patients, metastasis is limited and surgery or local treatment is possible, so an individualized strategy is needed.
In actual practice, “accurate subtype classification + appropriate initial treatment + surveillance for recurrence” remains the key pillar that determines prognosis. Recent research continues to attempt to combine pathological and genetic classification, immune microenvironment markers, clinical risk models, and so on to predict prognosis more precisely.
Prevention
Because no clear lifestyle cause is identified for most soft tissue sarcomas, there is no reliable method about which one can tell the general population, “doing this will prevent it.” Nevertheless, the realistically helpful direction for prevention is “reducing unnecessary risks and increasing the chance of early detection.”
For chemicals suspected of occupational exposure (certain herbicide ingredients, vinyl chloride, etc.), the principle is to follow safety rules, wear protective equipment, and minimize exposure. Medically, when radiation therapy is needed, the benefit of treatment is far greater, so rather than avoiding radiation, it is important to receive “only as much as needed, with an accurate plan.” Modern radiation therapy has greatly advanced in techniques for protecting normal tissue and is designed to reduce the risk compared with the past.
For people with a hereditary cancer syndrome, consulting a specialist to establish a personalized surveillance strategy can be helpful. In addition, because the risk of diseases such as Kaposi sarcoma can increase in immunocompromised states, managing infections and immune status may be important.
The most practical “preventive effect” comes from early evaluation. If a newly developed lump grows, is 5 cm or larger, is located deep, or is accompanied by pain or neurological symptoms of unknown cause, seeking medical care without delay and deciding on imaging tests and biopsy is the most realistic strategy for reducing recurrence and metastasis.